SCHEMBL3183303

SCHEMBL3183303

CN(C)CCc1c[nH]c2cccc(O[PH2]=O)c12

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 4/20 0.71
HTR2A P28223 11/20 0.66
HTR2C P28335 6/20 0.66
HTR2B P41595 6/20 0.66
HTR1A P08908 6/20 0.66
HTR1B P28222 2/20 0.59
HTR7 P34969 2/20 0.59
HTR5A P47898 2/20 0.59
DRD1 P21728 1/20 0.59
HTR1D P28221 1/20 0.59
HTR1E P28566 1/20 0.59
ADORA2A P29274 1/20 0.59
ADORA2B P29275 1/20 0.59
DRD3 P35462 1/20 0.59
HTR1F P30939 1/20 0.50
SLC6A4 P31645 1/20 0.50
SLC6A2 P23975 1/20 0.47
MTNR1A P48039 1/20 0.45
MTNR1B P49286 1/20 0.45
ADRA2A P08913 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25074609 0.85 HTR6 (0.73) HTR6HTR2AHTR2CHTR2BHTR1A
SCHEMBL29758535 0.83 HTR6 (1.00) HTR6HTR2AHTR2CHTR2BHTR1A
SCHEMBL29993252 0.83 HTR6 (1.00) HTR6HTR2AHTR2CHTR2BHTR1A
SCHEMBL19235737 0.83 HTR6 (1.00) HTR6HTR2AHTR2CHTR2BHTR1A
Hydrochloric Acid SCHEMBL4208783 0.82 HTR6 (0.97) HTR6HTR2AHTR2CHTR2BHTR1A
SCHEMBL26965639 0.82 HTR6 (0.77) HTR6HTR2AHTR2CHTR2BHTR1A
SCHEMBL29168531 0.82 HTR6 (0.71) HTR6HTR2AHTR2CHTR2BHTR1A
SCHEMBL26323272 0.82 HTR6 (0.71) HTR6HTR2AHTR2CHTR2BHTR1A
SCHEMBL22800104 0.82 HTR6 (0.71) HTR6HTR2AHTR2CHTR2BHTR1A
SCHEMBL4225666 0.81 HTR6 (0.70) HTR6HTR2AHTR2CHTR2BHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260090957-A1 Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness DRESDNER JR KARL P (US) 2026-04-02 US claimed
WO-2024254645-A1 COMPOSITION AND METHOD TO TREAT, AMELIORATE OR PREVENT A PSYCHOLOGICAL, NEUROLOGICAL OR INFLAMMATORY DISORDER, AND METHOD FOR PREPARING COMPOSITION Psychae Therapeutics Pty Ltd (AU) 2024-12-19 WO claimed
WO-2024097868-A1 STRUCTURE-ACTIVITY RELATIONSHIPS FOR PSILOCYBIN, BAEOCYSTIN, AERUGINASCIN, AND RELATED ANALOGUES TO PRODUCE PHARMACOLOGICAL EFFECTS CAAMTECH, INC. (US) 2024-05-10 WO claimed
US-11723894-B2 Combination product for the treatment of neurological and/or psychiatric disorders TERRAN BIOSCIENCES, INC. (US) 2023-08-15 US claimed
US-20260137652-A1 Composition Comprising Non-Phosphorylated Tryptamine SINTALICA S R L (IT) 2026-05-21 US disclosed
US-12622940-B2 Combined fungal composition for modulating an inflammatory response TURTLE BEAR HOLDINGS, LLC (US) 2026-05-12 US disclosed
US-12622938-B2 Compositions and methods for modulating inflammatory response TURTLE BEAR HOLDINGS, LLC (US) 2026-05-12 US disclosed
US-20260108493-A1 COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND CAAMTECH, INC. (US) 2026-04-23 US disclosed
US-20260108544-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS LLC (US) 2026-04-23 US disclosed
US-12606543-B2 Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto MINDSET PHARMA INC. (CA) 2026-04-21 US disclosed
US-20260102416-A1 COMPOSITION OF MATTER FOR TREATING AT A MEDICAL CONDITION AND METHODS OF USE AND MANUFACTURE THEREOF TLCO HOLDINGS INC. (US) 2026-04-16 US disclosed
US-20260098286-A1 Low Dose Psilocybin in Foodstuff and Microbes for Same ATX PHARMERS LLC (US) 2026-04-09 US disclosed
US-20180021326-A1 Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin TURTLE BEAR HOLDINGS, LLC 2018-01-25 US disclosed
US-8071786-B2 Indole compounds useful as serotonin selective agents GALENEA CORP. (US) 2011-12-06 US disclosed
EP-2254865-A1 INDOLE COMPOUNDS AND METHODS OF USE THEREOF ORGANIX, INC. (US) 2010-12-01 EP disclosed
US-20100137616-A1 INDOLE COMPOUNDS USEFUL AS SEROTONIN SELECTIVE AGENTS SARD HOWARD P 2010-06-03 US disclosed
US-7655691-B2 Indole compounds useful as serotonin selective agents ORGANIX, INC. 2010-02-02 US disclosed
US-20090318527-A1 INDOLE COMPOUNDS AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-12-24 US disclosed
WO-2009102805-A1 INDOLE COMPOUNDS AND METHODS OF USE THEREOF ORGANIX INC. (US) 2009-08-20 WO disclosed
US-20060100266-A1 Indole compounds useful as serotonin selective agents ORGANIX, INC. (US) 2006-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622940-B2 Combined fungal composition for modulating an inflammatory response SORD, ERG28, IL1B HTR6 3987/4885HTR2A 3723/4885HTR2C 3104/4885
US-20090318527-A1 INDOLE COMPOUNDS AND METHODS OF USE THEREOF IDO1, IDO2, INMT HTR6 8/4885HTR2A 27/4885HTR2C 30/4885
US-20100137616-A1 INDOLE COMPOUNDS USEFUL AS SEROTONIN SELECTIVE AGENTS TPH1, TPH2, AANAT HTR6 4/4885HTR2A 11/4885HTR2C 15/4885
US-12622938-B2 Compositions and methods for modulating inflammatory response IL1B, IL1R1, ERG28 HTR6 2601/4885HTR2A 3228/4885HTR2C 2332/4885
US-20260098286-A1 Low Dose Psilocybin in Foodstuff and Microbes for Same PNMT, MYCBP, TPH1 HTR6 5/4885HTR2A 6/4885HTR2C 8/4885
US-20260102416-A1 COMPOSITION OF MATTER FOR TREATING AT A MEDICAL CONDITION AND METHODS OF USE AND MANUFACTURE THEREOF PDE8B, MGLL, PDE3B HTR6 89/4885HTR2A 52/4885HTR2C 27/4885
US-20260108493-A1 COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND ADRA2C, ADRB3, ADRA2B HTR6 16/4885HTR2A 19/4885HTR2C 12/4885
US-20260137652-A1 Composition Comprising Non-Phosphorylated Tryptamine HTR2B, BDNF, HTR3B HTR6 30/4885HTR2A 31/4885HTR2C 17/4885
US-20260090957-A1 Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness QPCT, SLC38A7, QPCTL HTR6 2030/4885HTR2A 2610/4885HTR2C 1076/4885
US-11723894-B2 Combination product for the treatment of neurological and/or psychiatric disorders HTR2A, HTR2C, HTR1A HTR6 7/4885HTR2A 1/4885HTR2C 2/4885
US-20180021326-A1 Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin NES, PNMT, NGF HTR6 182/4885HTR2A 112/4885HTR2C 199/4885
US-20060100266-A1 Indole compounds useful as serotonin selective agents TPH1, TPH2, AANAT HTR6 4/4885HTR2A 11/4885HTR2C 15/4885
US-12606543-B2 Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto HTR6, CNR1, HTR3C HTR6 1/4885HTR2A 15/4885HTR2C 4/4885
US-20260108544-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, HTR6, BDNF HTR6 2/4885HTR2A 9/4885HTR2C 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.